BiotechTube

Placebo + KRN23

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

X-linked Hypophosphatemia

Conditions

X-linked Hypophosphatemia

Trial Timeline

Dec 1, 2008 → May 1, 2013

NCT ID
NCT00830674

About Placebo + KRN23

Placebo + KRN23 is a phase 1 stage product being developed by Kyowa Kirin for X-linked Hypophosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00830674. Target conditions include X-linked Hypophosphatemia.

What happened to similar drugs?

2 of 8 similar drugs in X-linked Hypophosphatemia were approved

Approved (2) Terminated (0) Active (6)
🔄KRN23Kyowa KirinPhase 3
🔄burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3
🔄burosumabKyowa KirinPhase 3
✅KRN23Kyowa KirinApproved
🔄BurosumabKyowa KirinPhase 3
🔄BurosumabKyowa KirinPhase 3
🔄burosumabKyowa KirinPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00830674Phase 1Completed

Competing Products

20 competing products in X-linked Hypophosphatemia

See all competitors
ProductCompanyStageHype Score
VK0214Viking TherapeuticsPhase 1
26
Methylprednisolone + Prednisolone + SirolimusAstellas PharmaPhase 1/2
39
BurosumabKyowa KirinPhase 1/2
32
BurosumabKyowa KirinPre-clinical
30
BurosumabKyowa KirinPre-clinical
26
BurosumabKyowa KirinPhase 2
35
KRN23Kyowa KirinPhase 1/2
32
KRN23Kyowa KirinPhase 3
40
burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3
40
burosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinApproved
43
burosumabKyowa KirinPhase 2
35
BurosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinPhase 1/2
32
BurosumabKyowa KirinPhase 3
40
burosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinPhase 2
35
KRN23Kyowa KirinPhase 1
29
KRN23Kyowa KirinApproved
43
KK8123Kyowa KirinPhase 1/2
39